Larry Ziye LiuPh.D., President and CEO
Charlene HudsonDirector, Business Development
Kenneth A. BrownePh.D., Director of R&D, Molecular Diagnostics
Jerry Xiaolin LiPh.D., Director, Technology and Marketing
Mr. Lixin Xu is the Vice President of Guangzhou Improve Medical Instruments Co. Ltd, the parent company of GIMDx,Inc and the Managing Director of ImproveX, a Improve Medical owned start-up Incubator based in Guangzhou, China. He has more than 20 years’ experience in R & D management of medical device industry. He served Johnson & Johnson, Philips Medical and HP/Agilent Medical from 1994-2010 before joining the top management team of Improve Medical. He has completed more than ten new product development projects, and presided over a series of investments in Guangzhou Hecin healthtech, Shenzhen Rosvent Medical, Shenzhen KaiRuikang, Guangzhou Yibu medical and Guangzhou TreatGut, and co-founded HiMed Angel Fund Management Co., Ltd. Lixin received his B.S. and M.S. degrees in Electronics Engineering from Xi’an Jiaotong University. He also holds a EMBA degree from China Europe International Business School.
Larry Ziye Liu founded GIMDx with financial support from Guangzhou Improve Medical Company, China in 2014, and he is President and CEO of the company. He has worked as a Virologist, Molecular Biologist and Biochemist in academia and industry for more than 30 years. In multidisciplinary, team environments, Larry was a Group Leader in Protein Development at BPS Bioscience in San Diego, California from 2011 to 2014, and he was a Scientist/Senior Scientist in Drug Discovery at Lexicon Pharmaceuticals in The Woodlands, Texas from 2004 to 2011. Prior to that, Larry’s background spanned the fields of Gene Engineering, Enzymology, Glycobiology and Structure Biology of Proteins in universities including Osaka University, University of Florida, Wayne State University and University of Toronto. His last academic position was as Research Assistant Professor at Ohio State University in 2004. Larry received B.S. and Ph.D. degrees in Virology from Wuhan University, China.
Charlene Hudson is an accomplished biotechnology professional with 20 years’ experience specializing in the clinical and molecular in vitro diagnostic industry. Known for cultivating enterprising relationships with customers and clients, Charlene has a strong track record of implementing innovative technologies and products in complex environments and for delivering sophisticated scientific information throughout all levels of the clinical laboratory. Prior to joining GIMDx, Charlene created and executed comprehensive strategies for new product adoption while at Ortho Clinical Diagnostics, Tm Bioscience and Luminex. At Access Genetics, Charlene began engaging in business development activities and while at DiaSorin, she developed marketing strategies for new product introduction. Charlene holds a B.S in Biology from Florida State University and an M.S. in Comparative and Experimental Medicine from the University of Tennessee, Knoxville.
Kenneth Browne has spent over 17 years in impacting the biotechnology industry with his strengths in experimental design and analysis, reagent formulation, and future product design and implementation. As a scientist and manager at GenProbe Incorporated (now Hologic), Ken developed new technologies in nucleic acid chemistry and molecular diagnostics, including ones for sample preparation, amplification, detection and assays. Additionally, he designed and developed decontamination reagents that are now part of Hologic’s product portfolio. Ken has authored more than 20 scientific publications and is named inventor on 7 issued U.S. patents and over 20 additional patents and applications worldwide. He was also cofounder of Inventis and Radian Biotechnology and serves on the scientific advisory board of NUBAD, a drug discovery company. Ken’s Ph.D. in Physical Organic Chemistry was conferred by the University of California at Santa Barbara.
Jerry Li is a biotechnology professional with 13 years industry experience in research, development and commercialization of therapeutic and diagnostics of immunological and other common human disorders. Prior to joining GIMDx, Jerry spent 5 years in China as Director of R&D in HOB Biotech Group and later in Vascutech to develop diagnostic reagents suitable for Chinese market in fields of allergy, autoimmunity and coagulation. Previously Jerry worked as a group leader in Orphagen Pharmaceuticals in the US to develop Th17 antagonist as a novel small molecule therapeutic for autoimmunity. Jerry received his Ph.D. from Duke University in Biochemistry and his B.S. from Beijing University in Biology.